EP0047013A1 - Subcutaneously implantable lead with drug dispenser means - Google Patents
Subcutaneously implantable lead with drug dispenser means Download PDFInfo
- Publication number
- EP0047013A1 EP0047013A1 EP81106829A EP81106829A EP0047013A1 EP 0047013 A1 EP0047013 A1 EP 0047013A1 EP 81106829 A EP81106829 A EP 81106829A EP 81106829 A EP81106829 A EP 81106829A EP 0047013 A1 EP0047013 A1 EP 0047013A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- drug
- lead
- electrode
- implantable lead
- body implantable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 229940079593 drug Drugs 0.000 title claims abstract description 61
- 230000000638 stimulation Effects 0.000 claims abstract description 16
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 239000011343 solid material Substances 0.000 claims abstract description 10
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 7
- 230000004761 fibrosis Effects 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 5
- 239000011248 coating agent Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 5
- 230000006793 arrhythmia Effects 0.000 claims abstract description 4
- 230000003204 osmotic effect Effects 0.000 claims abstract description 4
- 230000000717 retained effect Effects 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000004020 conductor Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 5
- 238000004891 communication Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000661 pacemaking effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/0565—Electrode heads
- A61N1/0568—Electrode heads with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/057—Anchoring means; Means for fixing the head inside the heart
Definitions
- Electrodes for medical purposes are well known in the prior art.
- An example of a device for this purpose is the well-known cardiac pacemaker.
- the stimulation is delivered to the desired body site by an electrode carrying lead.
- Interactions between the lead and body can vitiate the desired effects of the stimulation.
- material reactions may encourage fibrosis.
- fibrosis is believed to be a major factor in the increase in chronic threshold that is usually experienced.
- mechanical trauma may result in inflammation of the tissue to be stimulated. Such inflammation may alter the response of the tissue to the stimulation energy, both acutely and chronically.
- the body portion to be stimulated is irritable.
- the placement of a lead may compound this irritability.
- the placement of a pacemaking lead may induce a cardiac arrhythmia.
- the presence of the lead may also promote thrombus formation.
- the lead may be configured to reduce mechanical trauma and the response of irritable tissue during lead placement.
- Materials may be selected for the lead body and electrodes to minimize fibrosis. Thrombus formation may.. also be countered by the administration of suitable drugs. It is also known that a systemic treatment with steroids results in acute reduction in the threshold level.
- the present invention provides a body implantable lead for the delivery of stimulation energy to a desired body site which may be configured and constructed in accordance with known techniques while ameliorating the effects of undesirable interactions between the lead and body.
- a drug dispenser is carried by the lead and includes a member for retaining the drug to be dispensed while allowing a dispensing of that drug at least adjacent the desired body stimulation site.
- the drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any combination thereof, or to accomplish any other desirable localized purpose.
- the drug may be retained in liquid form in a reservoir including an agency for controlling the dispensing of the drug.
- the agency may be a semi-permeable membrane or, alternatively, the reservoir may be formed as an osmotic pump.
- the drug may be carried as a coating on a high surface area portion of the lead, or an electrode carried by the lead.
- the drug is compounded into a solid material with that solid material being carried by the. lead adjacent the electrode.
- the lead carries a tip electrode at its distal end with the drug being dispensed through the tip electrode.
- FIG. 1 illustrates a portion of a lead constructed in accordance with a preferred embodiment of the present invention including a lead body 10 formed of a conductor 11 and insulating sheath 12 and carrying at its distal end a tip electrode 13.
- the conductor 11 extends between the tip electrode 13 and a source of stimulation energy, in known manner.
- the conductor 11 is formed as a helically wound conductor, also in known manner.
- a drug dispenser indicated generally at 14 is carried by the lead and has tines 15 extending therefrom. Tines 15 are of known design and form no part of the present invention aside from forming a portion of the disclosed preferred embodiments thereof.
- FIG 2 is a cross-section taken along the line 2-2 in Figure 1 and illustrates drug dispenser 14 as an osmotic pump of generally known design.
- Pump 14 has inner and outer chambers 16 and 17, respectively, separated by an impermeable membrane 18.
- a semi-permeable membrane 19 forms the outer wall of chamber 17 while an extension 20 of electrode 13 extends into the chamber 16.
- the electrode 13 and its extension 20 are formed of a conductive material.
- the conductor 11 extends from the lead body 10 into the chamber 16 and into electrical communication with the extension 20 of electrode 13.
- the extension 20 of electrode 13 may be crimped as at 21 to maintain the electrical communication between it and the conductor 11.
- a seal 22 is provided in the chamber walls 18 and 19 at the point at which the conductor 11 passes through them.
- An end cap 23 closes the chamber 16.
- the chamber 16 Prior to implantation, the chamber 16 is charged with a drug to be dispensed.
- the drug may be any suitable drug intended to accomplish any desirable localized purpose.
- the drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any combination of drugs intended to accomplish one or more of those purposes, or any drug or combination of drugs intended to accomplish any other desirable localized purpose or purposes.
- the chamber 16 is charged through the extension 20 of electrode 13 with the drug passing into the chamber 16 between the coils of conductor 11 at the location between the end of the extension 20 of the electrode 13 and the seal 22.
- FIG 3 illustrates the outward configuration of a portion of a lead constructed in accordance with the preferred embodiments of Figures 4-6.
- like reference numerals indicate like elements including lead body 10, formed of conductor 11 and sheath 12, and tines 15.
- a distal tip electrode 13 is indicated generally at 13 in Figure 3 as is a drug dispenser 14.
- a tip electrode 111 is carried at the distal end of the lead and has a central bore which is filled with a solid material 24 which will be discussed more fully below.
- the electrode 13' extends from the distal end of the lead into electrical communication with the conductor 11. Electrical communication between the electrode 13' and conductor 11 may be established and maintained in any known manner.
- Material 24 within the central bore in electrode 13' is a complete material formed by compounding the drug to be dispensed, in solid form, with a solid material suitable for use as a carrier so as to form a permeable structure that allows the body fluids to enter and extract the compounded drug.
- the compounded drug must be water soluble.
- the carrier material may be a suitable silicone that is compounded with the drug to be dispensed and then placed in the central bore in the electrode 13'.
- the drug may be dispensed through the electrode 13' from the central bore of .the electrode 13'.
- ports may be provided between the central bore of electrode 13' to the sheath of the lead or side of the electrode as indicated at 25 to provide additional dispensing locations adjacent the electrode 13'.
- the central bore through the electrode 13' may be plugged with the dispensing being accomplished through the ports 25. Any number of ports 25 may be employed.
- FIG. 5 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3.
- a tip electrode 13" again has a central bore.
- that bore is closed by a semi-permeable membrane 26. Closing of the bore in electrode 13" by the membrane 26 forms a reservoir 27 within the bore.
- An access port 28 is provided through the sidewall of the seath to allow access to the reservoir 27.
- the member forming the access port 28 may be a self-sealing material such as silicone rubber which may be penetrated, as by a syringe, to charge the reservoir 27 while sealing the puncture from the syringe on withdrawal, in known manner.
- the reservoir 27 may be charged with'any suitable drug that it is desired to dispense and which has a molecular structure that will allow passage through the semi-permeable membrane to be dispensed by diffusion, in known manner.
- Figure 6 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3.
- the electrode 13"1 is formed of a sintered material, titanium, for example. Sintering of the electrode material provides a high surface area on which the drug to be dispensed may be deposited as a coating.
- the sintered electrode may be coated with the drug to be dispensed at the time of manufacture. Alternatively, the coating may be selectively applied at or prior to the time of implant of the lead.
- Figure 4 discloses an embodiment wherein the drug to be dispensed is compounded so as to form a composite material. That same process may be employed to form a composite material which may be employed to form the sheath 12 of the lead, the tines 15 or both.
- drugs to accomplish specific purposes are discussed herein, the invention is not limited to drugs that are useful to accomplish only those purposes.
- the particular conductor and sheath configurations form no part of the present invention. Indeed, the disclosed electrode configurations may be varied without departing from the scope of the present invention. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
- Electrical stimulation of the body for medical purposes is well known in the prior art. An example of a device for this purpose is the well-known cardiac pacemaker. In the pacemaker context, as well as other body stimulation contexts, the stimulation is delivered to the desired body site by an electrode carrying lead.
- Interactions between the lead and body can vitiate the desired effects of the stimulation. For example, material reactions may encourage fibrosis. In the pacemaking context, fibrosis is believed to be a major factor in the increase in chronic threshold that is usually experienced. Also, mechanical trauma may result in inflammation of the tissue to be stimulated. Such inflammation may alter the response of the tissue to the stimulation energy, both acutely and chronically.
- Other interactions between the lead and body, while not directly affecting the response of the tissue to the stimulation energy, can result in the occurrence of undesirable events. In some circumstances where electrical body stimulation is indicated, the body portion to be stimulated is irritable. The placement of a lead may compound this irritability. For example, the placement of a pacemaking lead may induce a cardiac arrhythmia. The presence of the lead may also promote thrombus formation.
- The interactions noted above have long been recognized and efforts made to ameliorate their consequences. For example, the lead may be configured to reduce mechanical trauma and the response of irritable tissue during lead placement. Materials may be selected for the lead body and electrodes to minimize fibrosis. Thrombus formation may.. also be countered by the administration of suitable drugs. It is also known that a systemic treatment with steroids results in acute reduction in the threshold level.
- The administration of drugs to counter the undesirable interactions between the lead and body noted above has not gained widespread acceptance in that it has heretofore required a systemic treatment to counter a localized interaction. Also, lead configuration must take into account other factors such as the efficiency of the delivery of the stimulation energy, the ease of lead placement, maintenance of the desired electrode position and reliability of the lead over extended periods of time. An accommodation of these interests has resulted in leads whose configuration necessarily results in undesirable interactions between the lead and body.
- The present invention provides a body implantable lead for the delivery of stimulation energy to a desired body site which may be configured and constructed in accordance with known techniques while ameliorating the effects of undesirable interactions between the lead and body. A drug dispenser is carried by the lead and includes a member for retaining the drug to be dispensed while allowing a dispensing of that drug at least adjacent the desired body stimulation site. The drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any combination thereof, or to accomplish any other desirable localized purpose. The drug may be retained in liquid form in a reservoir including an agency for controlling the dispensing of the drug. The agency may be a semi-permeable membrane or, alternatively, the reservoir may be formed as an osmotic pump. The drug may be carried as a coating on a high surface area portion of the lead, or an electrode carried by the lead. In a preferred embodiment, the drug is compounded into a solid material with that solid material being carried by the. lead adjacent the electrode. Most preferably, the lead carries a tip electrode at its distal end with the drug being dispensed through the tip electrode.
-
- Figure 1 illustrates a portion of a body implantable lead constructed in accordance with a preferred embodiment of the present invention.
- Figure 2 illustrates a cross-section taken along the line 2-2 in Figure 1.
- Figure 3 illustrates the configuration of a portion of a lead constructed in accordance with the preferred embodiments illustrated in Figures 4-6.
- Figures 4-6 illustrate alternative preferred embodiments viewed along the line 4-4 in Figure 3.
- Figure 1 illustrates a portion of a lead constructed in accordance with a preferred embodiment of the present invention including a
lead body 10 formed of a conductor 11 and insulatingsheath 12 and carrying at its distal end atip electrode 13. The conductor 11 extends between thetip electrode 13 and a source of stimulation energy, in known manner. In the illustrated embodiment, the conductor 11 is formed as a helically wound conductor, also in known manner. A drug dispenser indicated generally at 14 is carried by the lead and hastines 15 extending therefrom.Tines 15 are of known design and form no part of the present invention aside from forming a portion of the disclosed preferred embodiments thereof. - Figure 2 is a cross-section taken along the line 2-2 in Figure 1 and illustrates
drug dispenser 14 as an osmotic pump of generally known design.Pump 14 has inner andouter chambers impermeable membrane 18. Asemi-permeable membrane 19 forms the outer wall ofchamber 17 while anextension 20 ofelectrode 13 extends into thechamber 16. As is apparent to those skilled in the art, theelectrode 13 and itsextension 20 are formed of a conductive material. - The conductor 11 extends from the
lead body 10 into thechamber 16 and into electrical communication with theextension 20 ofelectrode 13. Theextension 20 ofelectrode 13 may be crimped as at 21 to maintain the electrical communication between it and the conductor 11. Aseal 22 is provided in thechamber walls end cap 23 closes thechamber 16. - Prior to implantation, the
chamber 16 is charged with a drug to be dispensed. The drug may be any suitable drug intended to accomplish any desirable localized purpose. For example, the drug may be one intended to counter thrombus formation, fibrosis, inflammation, or arrhythmias, or any combination of drugs intended to accomplish one or more of those purposes, or any drug or combination of drugs intended to accomplish any other desirable localized purpose or purposes. Thechamber 16 is charged through theextension 20 ofelectrode 13 with the drug passing into thechamber 16 between the coils of conductor 11 at the location between the end of theextension 20 of theelectrode 13 and theseal 22. After thechamber 16 is charged and the lead implanted, body fluids will enter thechamber 17 through thesemi-permeable membrane 19 to impart a pressure on thechamber 16 via theimpermeable membrane 18. This will result in a dispensing of the drug within thechamber 16 through theextension 20 of theelectrode 13 and theelectrode 13. - Figure 3 illustrates the outward configuration of a portion of a lead constructed in accordance with the preferred embodiments of Figures 4-6. Throughout the figures, like reference numerals indicate like elements including
lead body 10, formed of conductor 11 andsheath 12, and tines 15. Adistal tip electrode 13 is indicated generally at 13 in Figure 3 as is adrug dispenser 14. - Referring now to Figure 4, there is illustrated a preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3. A tip electrode 111 is carried at the distal end of the lead and has a central bore which is filled with a
solid material 24 which will be discussed more fully below. The electrode 13' extends from the distal end of the lead into electrical communication with the conductor 11. Electrical communication between the electrode 13' and conductor 11 may be established and maintained in any known manner. -
Material 24 within the central bore in electrode 13' is a complete material formed by compounding the drug to be dispensed, in solid form, with a solid material suitable for use as a carrier so as to form a permeable structure that allows the body fluids to enter and extract the compounded drug. For this purpose, the compounded drug must be water soluble. The carrier material may be a suitable silicone that is compounded with the drug to be dispensed and then placed in the central bore in the electrode 13'. The drug may be dispensed through the electrode 13' from the central bore of .the electrode 13'. Additionally, ports may be provided between the central bore of electrode 13' to the sheath of the lead or side of the electrode as indicated at 25 to provide additional dispensing locations adjacent the electrode 13'. Alternatively, the central bore through the electrode 13' may be plugged with the dispensing being accomplished through theports 25. Any number ofports 25 may be employed. - Figure 5 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3. In the embodiment of Figure 5, a
tip electrode 13" again has a central bore. However, in the embodiment of Figure 5 that bore is closed by asemi-permeable membrane 26. Closing of the bore inelectrode 13" by themembrane 26 forms a reservoir 27 within the bore. Anaccess port 28 is provided through the sidewall of the seath to allow access to the reservoir 27. The member forming theaccess port 28 may be a self-sealing material such as silicone rubber which may be penetrated, as by a syringe, to charge the reservoir 27 while sealing the puncture from the syringe on withdrawal, in known manner. The reservoir 27 may be charged with'any suitable drug that it is desired to dispense and which has a molecular structure that will allow passage through the semi-permeable membrane to be dispensed by diffusion, in known manner. - Figure 6 illustrates yet another preferred embodiment of the present invention as viewed along the line 4-4 in Figure 3. In Figure 6, the
electrode 13"1 is formed of a sintered material, titanium, for example. Sintering of the electrode material provides a high surface area on which the drug to be dispensed may be deposited as a coating. The sintered electrode may be coated with the drug to be dispensed at the time of manufacture. Alternatively, the coating may be selectively applied at or prior to the time of implant of the lead. - Obviously, many modifications and variations of the present invention are possible in light of the above teachings. For example, Figure 4 discloses an embodiment wherein the drug to be dispensed is compounded so as to form a composite material. That same process may be employed to form a composite material which may be employed to form the
sheath 12 of the lead, thetines 15 or both. Also, while drugs to accomplish specific purposes are discussed herein, the invention is not limited to drugs that are useful to accomplish only those purposes. Further, apart from forming a part of the delivery system for the electrical stimulation energy, the particular conductor and sheath configurations form no part of the present invention. Indeed, the disclosed electrode configurations may be varied without departing from the scope of the present invention. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18296380A | 1980-09-02 | 1980-09-02 | |
US182963 | 1988-04-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0047013A1 true EP0047013A1 (en) | 1982-03-10 |
EP0047013B1 EP0047013B1 (en) | 1986-01-22 |
Family
ID=22670818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP81106829A Expired EP0047013B1 (en) | 1980-09-02 | 1981-09-01 | Subcutaneously implantable lead with drug dispenser means |
Country Status (5)
Country | Link |
---|---|
US (1) | US4711251B1 (en) |
EP (1) | EP0047013B1 (en) |
JP (1) | JPS625174Y2 (en) |
CA (1) | CA1174284A (en) |
DE (1) | DE3173564D1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
US4577642A (en) * | 1985-02-27 | 1986-03-25 | Medtronic, Inc. | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication |
US4606118A (en) * | 1985-02-27 | 1986-08-19 | Medtronic, Inc. | Method of making a drug dispensing body |
EP0233986A1 (en) * | 1985-08-12 | 1987-09-02 | Fresenius AG | Intraperitoneal catheter for the administration of liquid medicines, particularly insulin |
DE3739826A1 (en) * | 1986-11-24 | 1988-07-14 | Telectronics Nv | IMPLANTABLE STIMULATION LINE FOR A HEART PACEMAKER |
FR2616072A1 (en) * | 1987-06-04 | 1988-12-09 | Ela Medical Sa | IMPROVEMENTS AT THE CONDUCTIVE END OF HEART STIMULATION PROBES |
US4819661A (en) * | 1987-10-26 | 1989-04-11 | Cardiac Pacemakers, Inc. | Positive fixation cardiac electrode with drug elution capabilities |
US4844099A (en) * | 1986-11-24 | 1989-07-04 | Telectronics, N.V. | Porous pacemaker electrode tip using a porous substrate |
EP0361762A2 (en) * | 1988-09-22 | 1990-04-04 | Med Institute, Inc. | Apparatus for treating tissue |
US4922926A (en) * | 1987-10-16 | 1990-05-08 | Siemens Aktiengesellschaft | Arrangement for delivering medications in an implantable medical device |
EP0388480A1 (en) * | 1989-03-20 | 1990-09-26 | Siemens Aktiengesellschaft | Implantable stimulation electrode |
EP0468636A1 (en) * | 1990-06-18 | 1992-01-29 | Boaz Avitall | Implantable iontophoretic delivery system |
EP0491082A1 (en) * | 1990-12-19 | 1992-06-24 | Peter Dr. Ing. Osypka | Pacemaker lead with an inner duct and with an electrode head |
WO1993021973A1 (en) * | 1992-04-24 | 1993-11-11 | Loma Linda University Medical Center | Cerebrospinal fluid shunt capable of minimal invasive revision |
FR2693115A1 (en) * | 1992-07-02 | 1994-01-07 | Celsa Lg | Implantable cardiac stimulation electrical unit - retards the medicament distribution near to electrode until electrode is positioned at stimulation area |
EP0627237A1 (en) * | 1991-06-26 | 1994-12-07 | Hector Osvaldo Trabucco | Pacemaker |
WO1997029802A2 (en) * | 1996-02-20 | 1997-08-21 | Advanced Bionics Corporation | Improved implantable microstimulator and systems employing the same |
WO1998051369A1 (en) * | 1997-05-13 | 1998-11-19 | Edwards Stuart D | Global medical treatment method and apparatus |
WO2000067839A1 (en) * | 1999-05-07 | 2000-11-16 | Cedars-Sinai Medical Center | Method and apparatus for inducing ventricular arrhythmias in test animals |
WO2007112520A2 (en) * | 2006-04-06 | 2007-10-11 | Lesors B.V.B.A. | Implantable venous perfusion device |
US8573398B2 (en) | 2002-05-28 | 2013-11-05 | Georgia-Pacific Consumer Products Lp | Refillable flexible sheet dispenser |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4819662A (en) * | 1987-10-26 | 1989-04-11 | Cardiac Pacemakers, Inc. | Cardiac electrode with drug delivery capabilities |
US6146358A (en) | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
WO1990012611A1 (en) * | 1989-04-21 | 1990-11-01 | Ash Medical Systems, Inc. | Non-intravascular infusion access device |
US5002067A (en) * | 1989-08-23 | 1991-03-26 | Medtronic, Inc. | Medical electrical lead employing improved penetrating electrode |
US4953564A (en) * | 1989-08-23 | 1990-09-04 | Medtronic, Inc. | Screw-in drug eluting lead |
US4972848A (en) * | 1989-08-23 | 1990-11-27 | Medtronic, Inc. | Medical electrical lead with polymeric monolithic controlled release device and method of manufacture |
US5003992A (en) * | 1989-08-23 | 1991-04-02 | Holleman Timothy W | Atraumatic screw-in lead |
US5020544A (en) * | 1989-11-01 | 1991-06-04 | Cardiac Pacemakers, Inc. | Low energy defibrillation electrode |
US5217028A (en) * | 1989-11-02 | 1993-06-08 | Possis Medical, Inc. | Bipolar cardiac lead with drug eluting device |
US5255693A (en) * | 1989-11-02 | 1993-10-26 | Possis Medical, Inc. | Cardiac lead |
US5009229A (en) * | 1989-12-06 | 1991-04-23 | Medtronic, Inc. | Steroid eluting intramuscular lead |
US5086787A (en) * | 1989-12-06 | 1992-02-11 | Medtronic, Inc. | Steroid eluting intramuscular lead |
US5049132A (en) * | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
US5111812A (en) * | 1990-01-23 | 1992-05-12 | Cardiac Pacemakers, Inc. | Defilbrillation electrode having smooth current distribution |
US5265608A (en) * | 1990-02-22 | 1993-11-30 | Medtronic, Inc. | Steroid eluting electrode for peripheral nerve stimulation |
US5092332A (en) * | 1990-02-22 | 1992-03-03 | Medtronic, Inc. | Steroid eluting cuff electrode for peripheral nerve stimulation |
US5081990A (en) * | 1990-05-11 | 1992-01-21 | New York University | Catheter for spinal epidural injection of drugs and measurement of evoked potentials |
US5282844A (en) * | 1990-06-15 | 1994-02-01 | Medtronic, Inc. | High impedance, low polarization, low threshold miniature steriod eluting pacing lead electrodes |
US5154182A (en) * | 1991-02-15 | 1992-10-13 | Siemens Pacesetter, Inc. | Drug or steroid releasing patch electrode for an implantable arrhythmia treatment system |
US5324325A (en) * | 1991-06-27 | 1994-06-28 | Siemens Pacesetter, Inc. | Myocardial steroid releasing lead |
SE9102778D0 (en) * | 1991-09-25 | 1991-09-25 | Siemens Elema Ab | IMPLANT MEDICAL DEVICE |
FR2690626B1 (en) * | 1992-04-30 | 1998-10-16 | Ela Medical Sa | PROBE FOR HEART STIMULATOR. |
US5318572A (en) * | 1992-06-02 | 1994-06-07 | Siemens Pacesetter, Inc. | High efficiency tissue stimulating and signal sensing electrode |
US5447533A (en) * | 1992-09-03 | 1995-09-05 | Pacesetter, Inc. | Implantable stimulation lead having an advanceable therapeutic drug delivery system |
US5324324A (en) * | 1992-10-13 | 1994-06-28 | Siemens Pacesetter, Inc. | Coated implantable stimulation electrode and lead |
US5330525A (en) * | 1993-04-29 | 1994-07-19 | Medtronic, Inc. | Epicardial lead having dual rotatable anchors |
US5408744A (en) * | 1993-04-30 | 1995-04-25 | Medtronic, Inc. | Substrate for a sintered electrode |
DE69405406T2 (en) * | 1993-10-29 | 1998-04-02 | Medtronic Inc | METHOD FOR PRODUCING A MEDICAL STIMULATION ELECTRODE |
US5397343A (en) * | 1993-12-09 | 1995-03-14 | Medtronic, Inc. | Medical electrical lead having counter fixation anchoring system |
US5423876A (en) * | 1993-12-09 | 1995-06-13 | Medtronic, Inc. | Intramuscular lead having improved insertion |
US5489294A (en) * | 1994-02-01 | 1996-02-06 | Medtronic, Inc. | Steroid eluting stitch-in chronic cardiac lead |
US5443492A (en) * | 1994-02-02 | 1995-08-22 | Medtronic, Inc. | Medical electrical lead and introducer system for implantable pulse generator |
US5496360A (en) * | 1994-04-12 | 1996-03-05 | Ventritex, Inc. | Implantable cardiac electrode with rate controlled drug delivery |
US5545207A (en) * | 1994-08-24 | 1996-08-13 | Medtronic, Inc. | Medical electrical lead having stable fixation system |
US5582591A (en) * | 1994-09-02 | 1996-12-10 | Delab | Delivery of solid drug compositions |
US5837276A (en) * | 1994-09-02 | 1998-11-17 | Delab | Apparatus for the delivery of elongate solid drug compositions |
US5562723A (en) | 1994-10-06 | 1996-10-08 | Medtronic, Inc. | Medical electrical lead having a reinforced tine assembly |
US5741319A (en) * | 1995-01-27 | 1998-04-21 | Medtronic, Inc. | Biocompatible medical lead |
US5704915A (en) * | 1995-02-14 | 1998-01-06 | Therex Limited Partnership | Hemodialysis access device |
US5871484A (en) * | 1995-11-09 | 1999-02-16 | General Orthopedics | Apparatus and method for administering a biologically active substance to a bone |
US5987746A (en) * | 1996-02-21 | 1999-11-23 | Medtronic, Inc. | Method of making medical electrical lead |
US6110155A (en) * | 1996-04-30 | 2000-08-29 | Medtronic, Inc. | Anti-inflammatory-agent-loaded catheter and method for preventing tissue fibrosis |
DE69736862T2 (en) | 1996-07-17 | 2007-05-31 | Medtronic, Inc., Minneapolis | Delivery system for delivery of genetic material to cardiac tissue |
AU2437397A (en) | 1996-07-17 | 1998-02-09 | Medtronic, Inc. | System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
WO1998015317A1 (en) | 1996-10-07 | 1998-04-16 | Sulzer Intermedics Inc. | Controllable drug injection electrode |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US6741877B1 (en) * | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US6477423B1 (en) * | 1997-05-28 | 2002-11-05 | Transneuronix, Inc. | Medical device for use in laparoscopic surgery |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6038482A (en) * | 1998-10-30 | 2000-03-14 | Pacesetter, Inc. | Open bore electrode with a tiered drug therapy delivery system |
US7637886B2 (en) | 1999-01-25 | 2009-12-29 | Atrium Medical Corporation | Expandable fluoropolymer device and method of making |
US6395208B1 (en) | 1999-01-25 | 2002-05-28 | Atrium Medical Corporation | Method of making an expandable fluoropolymer device |
US6955661B1 (en) | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US6304786B1 (en) * | 1999-03-29 | 2001-10-16 | Cardiac Pacemakers, Inc. | Implantable lead with dissolvable coating for improved fixation and extraction |
CA2380111A1 (en) * | 1999-08-03 | 2001-02-08 | Smith & Nephew, Inc. | Controlled release implantable devices |
US6363287B1 (en) | 1999-10-27 | 2002-03-26 | Medtronic, Inc. | Steroid elution electrodes LVCV, left atrial medical/elecrical leads |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US8086314B1 (en) | 2000-09-27 | 2011-12-27 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US7616997B2 (en) | 2000-09-27 | 2009-11-10 | Kieval Robert S | Devices and methods for cardiovascular reflex control via coupled electrodes |
US7840271B2 (en) | 2000-09-27 | 2010-11-23 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US7499742B2 (en) | 2001-09-26 | 2009-03-03 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US7623926B2 (en) | 2000-09-27 | 2009-11-24 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US6510348B2 (en) | 2000-12-20 | 2003-01-21 | Medtronic, Inc. | Perfusion lead and method of use |
US6567704B2 (en) | 2000-12-20 | 2003-05-20 | Medtronic, Inc. | Medical electrical lead and method of use |
US6901289B2 (en) | 2000-12-29 | 2005-05-31 | Medtronic, Inc. | System for providing electrical stimulation to a left chamber of a heart |
US6934589B2 (en) | 2000-12-29 | 2005-08-23 | Medtronic, Inc. | System and method for placing endocardial leads |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
SE0101154D0 (en) * | 2001-03-29 | 2001-03-29 | St Jude Medical | An electrically conductive lead and a method of producing such a lead |
AU2002309528A1 (en) | 2001-04-02 | 2002-10-15 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6632217B2 (en) * | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
US20040236377A1 (en) * | 2001-07-02 | 2004-11-25 | Medtronic, Inc. | System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6999819B2 (en) | 2001-08-31 | 2006-02-14 | Medtronic, Inc. | Implantable medical electrical stimulation lead fixation method and apparatus |
US6978185B2 (en) * | 2001-11-09 | 2005-12-20 | Oscor Inc. | Multifilar conductor for cardiac leads |
US7187980B2 (en) * | 2001-11-09 | 2007-03-06 | Oscor Inc. | Cardiac lead with steroid eluting ring |
WO2003046504A1 (en) | 2001-11-26 | 2003-06-05 | Sielte S.P.A. | System and method for monitoring optical fiber cables |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
AU2003220574A1 (en) | 2002-03-27 | 2003-10-13 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US7177704B2 (en) | 2002-04-29 | 2007-02-13 | Medtronic, Inc. | Pacing method and apparatus |
US6978178B2 (en) * | 2002-04-30 | 2005-12-20 | Medtronic, Inc. | Method and apparatus for selecting an optimal electrode configuration of a medical electrical lead having a multiple electrode array |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7082335B2 (en) * | 2002-09-30 | 2006-07-25 | Medtronic, Inc. | Multipolar pacing method and apparatus |
US7363244B2 (en) * | 2002-11-08 | 2008-04-22 | Palo Alto Research Center Incorporated | Methods, apparatus, and program products for inferring service usage |
US20040102830A1 (en) * | 2002-11-22 | 2004-05-27 | Williams Terrell M. | System for coupling an implanatable medical device to an epicardial site |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
WO2007120442A2 (en) | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7925321B2 (en) | 2003-08-01 | 2011-04-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8676287B2 (en) | 2003-08-01 | 2014-03-18 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7494465B2 (en) | 2004-07-13 | 2009-02-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7953499B2 (en) * | 2003-09-30 | 2011-05-31 | Cardiac Pacemakers, Inc. | Drug-eluting electrode |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
JP2007516742A (en) * | 2003-11-20 | 2007-06-28 | アンジオテック インターナショナル アーゲー | Electrical devices and anti-scarring agents |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
DE602004029092D1 (en) | 2003-12-05 | 2010-10-21 | Dexcom Inc | CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTIC SENSOR |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
WO2005057175A2 (en) | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US7526336B2 (en) * | 2004-03-05 | 2009-04-28 | Pacesetter, Inc. | Left heart implantable cardiac stimulation system with clot prevention and method |
US8099174B1 (en) | 2004-03-05 | 2012-01-17 | Pacesetter, Inc. | Left heart implantable cardiac stimulation system with clot prevention electrode body coating and method |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US7720550B2 (en) * | 2004-12-03 | 2010-05-18 | Medtronic, Inc. | High impedance active fixation electrode of an electrical medical lead |
US20060240060A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Lubricious compound and medical device made of the same |
US20060241000A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Lubricious compound and medical device made of the same |
US20060240253A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Guidewire and tube with lubricious coating |
US20060240059A1 (en) * | 2005-04-22 | 2006-10-26 | Cardiac Pacemakers, Inc. | Lubricious eluting polymer blend and coating made from the same |
US20060247750A1 (en) * | 2005-04-28 | 2006-11-02 | Seifert Kevin R | Guide catheters for accessing cardiac sites |
US7974710B2 (en) * | 2005-04-28 | 2011-07-05 | Medtronic, Inc. | Guide catheters for accessing cardiac sites |
US20070100411A1 (en) * | 2005-10-27 | 2007-05-03 | Medtronic, Inc. | Implantable medical electrical stimulation lead fixation method and apparatus |
EP3513708B1 (en) | 2006-03-09 | 2022-12-28 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US20080071158A1 (en) | 2006-06-07 | 2008-03-20 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
US20070299491A1 (en) * | 2006-06-22 | 2007-12-27 | Harshad Borgaonkar | Drug-eluting coating on shocking coil of tachy lead and methods related thereto |
JP2008126000A (en) * | 2006-11-24 | 2008-06-05 | Terumo Corp | Medical implement, medical apparatus and method of manufacturing medical implement |
US20080288017A1 (en) * | 2007-02-27 | 2008-11-20 | Cvrx, Inc. | External Baroreflex Activation |
US20200037874A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US20080306444A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8594794B2 (en) | 2007-07-24 | 2013-11-26 | Cvrx, Inc. | Baroreflex activation therapy with incrementally changing intensity |
EP2195078B1 (en) | 2007-08-20 | 2013-10-09 | Medtronic, Inc. | Implantable medical lead with biased electrode |
US8326418B2 (en) | 2007-08-20 | 2012-12-04 | Medtronic, Inc. | Evaluating therapeutic stimulation electrode configurations based on physiological responses |
WO2009025816A1 (en) * | 2007-08-20 | 2009-02-26 | Medtronic, Inc. | Electrode configurations for directional leads |
US8190271B2 (en) * | 2007-08-29 | 2012-05-29 | Advanced Bionics, Llc | Minimizing trauma during and after insertion of a cochlear lead |
US8271101B2 (en) | 2007-08-29 | 2012-09-18 | Advanced Bionics | Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead |
EP4159114B1 (en) | 2007-10-09 | 2024-04-10 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8275468B2 (en) * | 2008-07-03 | 2012-09-25 | Cardiac Pacemakers, Inc. | Helical fixation member with chemical elution capabilities |
US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US8936630B2 (en) | 2009-11-25 | 2015-01-20 | Medtronic, Inc. | Optical stimulation therapy |
EP2600936B1 (en) | 2010-08-06 | 2018-09-19 | Cardiac Pacemakers, Inc. | User interface system for use with multipolar pacing leads |
US9872983B2 (en) | 2010-10-27 | 2018-01-23 | Dignity Health | Uterine electrical stimulation system and method |
CA2816073C (en) | 2010-10-27 | 2018-12-18 | Dignity Health | Uterine electrical stimulation system and method |
US9848809B2 (en) | 2011-04-15 | 2017-12-26 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US9592398B2 (en) | 2011-05-12 | 2017-03-14 | Medtronic, Inc. | Leadless implantable medical device with osmotic pump |
DK3700416T3 (en) | 2017-10-24 | 2024-09-30 | Dexcom Inc | PRE-CONNECTED ANALYTE SENSORS |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476116A (en) * | 1967-11-09 | 1969-11-04 | Victor Parsonnet | Nonpolarizing electrode for physiological stimulation |
FR2109932A5 (en) * | 1970-10-01 | 1972-05-26 | Tecna Corp | |
FR2195461A1 (en) * | 1972-08-10 | 1974-03-08 | Siemens Ag | |
US3829903A (en) * | 1972-12-11 | 1974-08-20 | Dow Corning | Method of inhibiting blood clot on silicone rubber medical devices |
US3932656A (en) * | 1970-09-10 | 1976-01-13 | Alza Corporation | Article of manufacture for instant release of anti-aggregation and non-thrombogenic agents to biological media |
US4033357A (en) * | 1975-02-07 | 1977-07-05 | Medtronic, Inc. | Non-fibrosing cardiac electrode |
GB1552388A (en) * | 1976-05-14 | 1979-09-12 | Macgregor D C | Cardiovascular prostheses |
DE3000114A1 (en) * | 1979-01-04 | 1980-07-24 | Vnii Ispytatel Med Tech | CONNECTING ELEMENT FOR FIXING BONE TISSUES |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3568660A (en) * | 1967-11-20 | 1971-03-09 | Battelle Development Corp | Pacemaker catheter |
US3680544A (en) * | 1970-09-09 | 1972-08-01 | James P Shinnick | Transthoracic cannula-type device for cardiopulmonary resuscitation |
US4055178A (en) * | 1976-03-10 | 1977-10-25 | Harrigan Roy Major | Drug delivery device for preventing contact of undissolved drug with the stomach lining |
DE2842318C2 (en) * | 1978-09-28 | 1985-05-23 | Siemens AG, 1000 Berlin und 8000 München | Implantable carbon electrode |
-
1981
- 1981-09-01 DE DE8181106829T patent/DE3173564D1/en not_active Expired
- 1981-09-01 JP JP1981130302U patent/JPS625174Y2/ja not_active Expired
- 1981-09-01 EP EP81106829A patent/EP0047013B1/en not_active Expired
- 1981-09-01 CA CA000385012A patent/CA1174284A/en not_active Expired
-
1983
- 1983-03-31 US US06480913 patent/US4711251B1/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476116A (en) * | 1967-11-09 | 1969-11-04 | Victor Parsonnet | Nonpolarizing electrode for physiological stimulation |
US3932656A (en) * | 1970-09-10 | 1976-01-13 | Alza Corporation | Article of manufacture for instant release of anti-aggregation and non-thrombogenic agents to biological media |
FR2109932A5 (en) * | 1970-10-01 | 1972-05-26 | Tecna Corp | |
FR2195461A1 (en) * | 1972-08-10 | 1974-03-08 | Siemens Ag | |
US3829903A (en) * | 1972-12-11 | 1974-08-20 | Dow Corning | Method of inhibiting blood clot on silicone rubber medical devices |
US4033357A (en) * | 1975-02-07 | 1977-07-05 | Medtronic, Inc. | Non-fibrosing cardiac electrode |
GB1552388A (en) * | 1976-05-14 | 1979-09-12 | Macgregor D C | Cardiovascular prostheses |
DE3000114A1 (en) * | 1979-01-04 | 1980-07-24 | Vnii Ispytatel Med Tech | CONNECTING ELEMENT FOR FIXING BONE TISSUES |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
US4577642A (en) * | 1985-02-27 | 1986-03-25 | Medtronic, Inc. | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication |
US4606118A (en) * | 1985-02-27 | 1986-08-19 | Medtronic, Inc. | Method of making a drug dispensing body |
EP0233986A1 (en) * | 1985-08-12 | 1987-09-02 | Fresenius AG | Intraperitoneal catheter for the administration of liquid medicines, particularly insulin |
DE3739826A1 (en) * | 1986-11-24 | 1988-07-14 | Telectronics Nv | IMPLANTABLE STIMULATION LINE FOR A HEART PACEMAKER |
US4784161A (en) * | 1986-11-24 | 1988-11-15 | Telectronics, N.V. | Porous pacemaker electrode tip using a porous substrate |
US4844099A (en) * | 1986-11-24 | 1989-07-04 | Telectronics, N.V. | Porous pacemaker electrode tip using a porous substrate |
FR2616072A1 (en) * | 1987-06-04 | 1988-12-09 | Ela Medical Sa | IMPROVEMENTS AT THE CONDUCTIVE END OF HEART STIMULATION PROBES |
EP0296001A1 (en) * | 1987-06-04 | 1988-12-21 | Ela Medical | Conducting extremites of cardiac stimulation electrodes |
US4922926A (en) * | 1987-10-16 | 1990-05-08 | Siemens Aktiengesellschaft | Arrangement for delivering medications in an implantable medical device |
US4819661A (en) * | 1987-10-26 | 1989-04-11 | Cardiac Pacemakers, Inc. | Positive fixation cardiac electrode with drug elution capabilities |
EP0361762A2 (en) * | 1988-09-22 | 1990-04-04 | Med Institute, Inc. | Apparatus for treating tissue |
EP0361762A3 (en) * | 1988-09-22 | 1992-01-08 | Med Institute, Inc. | Apparatus for treating tissue |
EP0388480A1 (en) * | 1989-03-20 | 1990-09-26 | Siemens Aktiengesellschaft | Implantable stimulation electrode |
US5103837A (en) * | 1989-03-20 | 1992-04-14 | Siemens Aktiengesellschaft | Implantable stimulating electrode |
EP0468636A1 (en) * | 1990-06-18 | 1992-01-29 | Boaz Avitall | Implantable iontophoretic delivery system |
US5261419A (en) * | 1990-12-19 | 1993-11-16 | Peter Osypka | Cardiac pacemaker lead |
EP0491082A1 (en) * | 1990-12-19 | 1992-06-24 | Peter Dr. Ing. Osypka | Pacemaker lead with an inner duct and with an electrode head |
EP0627237A1 (en) * | 1991-06-26 | 1994-12-07 | Hector Osvaldo Trabucco | Pacemaker |
WO1993021973A1 (en) * | 1992-04-24 | 1993-11-11 | Loma Linda University Medical Center | Cerebrospinal fluid shunt capable of minimal invasive revision |
US5385541A (en) * | 1992-04-24 | 1995-01-31 | Loma Linda University Medical Center | Cerebrospinal fluid shunt capable of minimal invasive revision |
FR2693115A1 (en) * | 1992-07-02 | 1994-01-07 | Celsa Lg | Implantable cardiac stimulation electrical unit - retards the medicament distribution near to electrode until electrode is positioned at stimulation area |
US6175764B1 (en) | 1996-02-20 | 2001-01-16 | Advanced Bionics Corporation | Implantable microstimulator system for producing repeatable patterns of electrical stimulation |
US6214032B1 (en) | 1996-02-20 | 2001-04-10 | Advanced Bionics Corporation | System for implanting a microstimulator |
US6051017A (en) * | 1996-02-20 | 2000-04-18 | Advanced Bionics Corporation | Implantable microstimulator and systems employing the same |
WO1997029802A3 (en) * | 1996-02-20 | 1997-11-13 | Advanced Bionics Corp | Improved implantable microstimulator and systems employing the same |
WO1997029802A2 (en) * | 1996-02-20 | 1997-08-21 | Advanced Bionics Corporation | Improved implantable microstimulator and systems employing the same |
US6181965B1 (en) | 1996-02-20 | 2001-01-30 | Advanced Bionics Corporation | Implantable microstimulator system for prevention of disorders |
US6185455B1 (en) | 1996-02-20 | 2001-02-06 | Advanced Bionics Corporation | Method of reducing the incidence of medical complications using implantable microstimulators |
WO1998051369A1 (en) * | 1997-05-13 | 1998-11-19 | Edwards Stuart D | Global medical treatment method and apparatus |
WO2000067839A1 (en) * | 1999-05-07 | 2000-11-16 | Cedars-Sinai Medical Center | Method and apparatus for inducing ventricular arrhythmias in test animals |
US6351668B1 (en) | 1999-05-07 | 2002-02-26 | Cedars-Sinai Medical Center | Method for inducing ventricular arrhythmias in an animal model system |
US6353757B2 (en) | 1999-05-07 | 2002-03-05 | Cedars-Sinai Medical Center | Method for collecting data pertinent to predictors of heart arrhythmias using an animal test subject |
US6398800B2 (en) | 1999-05-07 | 2002-06-04 | Cedars-Sinai Medical Center | Method for testing a technique intended to predict onset of heart arrhythmia using an animal test subject |
US8573398B2 (en) | 2002-05-28 | 2013-11-05 | Georgia-Pacific Consumer Products Lp | Refillable flexible sheet dispenser |
WO2007112520A2 (en) * | 2006-04-06 | 2007-10-11 | Lesors B.V.B.A. | Implantable venous perfusion device |
FR2899486A1 (en) * | 2006-04-06 | 2007-10-12 | Lesors B V B A | IMPLANTABLE VENOUS INFUSION DEVICE |
WO2007112520A3 (en) * | 2006-04-06 | 2008-01-03 | Lesors B V B A | Implantable venous perfusion device |
Also Published As
Publication number | Publication date |
---|---|
US4711251B1 (en) | 1994-06-28 |
JPS625174Y2 (en) | 1987-02-05 |
JPS5770343U (en) | 1982-04-28 |
US4711251A (en) | 1987-12-08 |
EP0047013B1 (en) | 1986-01-22 |
CA1174284A (en) | 1984-09-11 |
DE3173564D1 (en) | 1986-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4711251A (en) | Body implantable lead | |
USH356H (en) | Epicardial lead having low threshold, low polarization myocardial electrode | |
US4506680A (en) | Drug dispensing body implantable lead | |
US4606118A (en) | Method of making a drug dispensing body | |
US5324325A (en) | Myocardial steroid releasing lead | |
US6363286B1 (en) | High impedance electrode assembly | |
EP2108399B1 (en) | Implantable neuro-stimulation electrode with fluid reservoir | |
US5041107A (en) | Electrically controllable, non-occluding, body implantable drug delivery system | |
US4953564A (en) | Screw-in drug eluting lead | |
US4360031A (en) | Drug dispensing irrigatable electrode | |
US6298272B1 (en) | High impedance electrode tip with internal drug delivery capability | |
US4577642A (en) | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication | |
US4819662A (en) | Cardiac electrode with drug delivery capabilities | |
US4784161A (en) | Porous pacemaker electrode tip using a porous substrate | |
US6671562B2 (en) | High impedance drug eluting cardiac lead | |
US5871529A (en) | Electrode for high impedance heart stimulation | |
US5154182A (en) | Drug or steroid releasing patch electrode for an implantable arrhythmia treatment system | |
US5632770A (en) | Implantable defibrillation system with lead having improved porous surface coating | |
US6038482A (en) | Open bore electrode with a tiered drug therapy delivery system | |
JPH06312025A (en) | Human body stimulating/sensing lead, its electrode, and manufacture of said electrode | |
JPH06190061A (en) | Electrode device for pacemaker | |
EP1224005B1 (en) | Steroid elution electrode assembly for left heart medical leads | |
EP2379165B1 (en) | Implantable and refillable drug delivery reservoir | |
EP1592479B1 (en) | Tachy lead system for septal placement | |
US8014857B2 (en) | Implantable shock electrode line and implantable defibrillation arrangement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): DE FR GB IT NL SE |
|
17P | Request for examination filed |
Effective date: 19820910 |
|
ITF | It: translation for a ep patent filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): DE FR GB IT NL SE |
|
REF | Corresponds to: |
Ref document number: 3173564 Country of ref document: DE Date of ref document: 19860306 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 81106829.5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19960624 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19960808 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19960819 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19960927 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970902 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19970905 Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980401 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19970901 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19980401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980603 |
|
EUG | Se: european patent has lapsed |
Ref document number: 81106829.5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990531 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |